x
CME-Tagline

Live Q&A Part 1: Clearing the Way for Better Treatment: Long-Term Relief for Patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)

CMEO Webcast

Premiere Date: Tuesday, June 7, 2022

This activity offers CE credit for:

  1. Medicine (accme)
  2. Nursing (ANCC)
  3. Pharmacy (acpe)
  4. PA (aapa)
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢

Credit Expiration Date: Wednesday, June 7, 2023

Faculty


Joseph K. Han, MD, FARS, FAAAAI Joseph K. Han, MD, FARS, FAAAAI (Moderator)
Professor
Chief, Division of Rhinology & Endoscopic Sinus and Skull Base Surgery
Chief, Division of Allergy
Eastern Virginia Medical School
Norfolk, VA
ARS, Immediate Past President
AAAAI, RROAC, Chair

Stella Lee, MD Stella Lee, MD 
Section Chief, Rhinology
Division of Otolaryngology-Head & Neck Surgery
Brigham and Women's Hospital
Harvard Medical School
Boston, MA

Statement of Need

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory disease characterized by rhinosinusitis and the development of polyposis originating in the sinus and eventually extending to the nose. Persistent symptoms include congestion, stuffiness, nasal discharge, facial pain and/or pressure, impairment, or loss of sense of smell, and fatigue. CRSwNP confers a substantial but often underappreciated burden, negatively impacting mental and physical health-related quality of life (HRQoL) endpoints. It is critical that health care professionals (HCPs) understand the burden of CRSwNP, the limitations of traditional therapy, and the potential benefits of biologic therapy on CRSwNP outcomes.

This live Q&A session is your opportunity to ask questions based on the CMEO Snack series that focused on recognizing the burden and impact of CRSwNP, translating the most recent guideline recommendations, and applying up to date safety and efficacy data to make the best treatment decisions for patients.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the burden of CRSwNP and the impact of this disease on patients' HRQoL and treatment response.
  • Translate updated guideline recommendations to treatment decisions for the management of uncontrolled CRSwNP.
  • Apply efficacy and safety data to treatment decisions for patients with CRSwNP.

Financial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

Physicians, PAs, nurse practitioners, nurses and pharmacists specializing in allergy/immunology, and otolaryngology practicing globally

Credit Information

EACCME:
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Creditâ„¢ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain certificate as proof of completion.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Han reports the following financial relationships:

Research Support: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme

Dr. Lee reports the following financial relationships:

Consultant and Research Support: AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; and Sanofi Regeneron

The following peer reviewer and CME Outfitters staff have no financial relationships:
  • Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
  • Janan Sarwar, PharmD (planning committee)
  • Kashemi D. Rorie, PhD (planning committee)
  • Evan Luberger (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    This document was last modified on:

    SNQ-163-060722-90